104064 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Rules and Regulations 

TABLE 1 TO PARAGRAPH (c)—EPA-APPROVED GEORGIA REGULATIONS—Continued 

State citation Title/subject 

State 

effective 

date 

EPA approval date Explanation 

391–3–20–.22 .............. Enforcement .................................................... 4/19/2022 2/9/2024, 89 FR 8996.

(d) EPA-approved Georgia sourcespecific requirements. 

TABLE 2 TO PARAGRAPH (d)—EPA-APPROVED GEORGIA SOURCE-SPECIFIC REQUIREMENTS

Name of source Permit No. 

State 

effective 

date 

EPA approval date Comments 

Georgia Power Plant Bowen ....... EPD–AQC–180 ............................................................................... 11/17/1980 8/17/1981, 46 FR 41498.

Georgia Power Plant Harllee 

Branch.

4911–117–6716–0 .......................................................................... 4/23/1980 5/5/1981, 46 FR 25092.

ITT Rayonier, Inc ........................ 2631–151–7686–C .......................................................................... 11/4/1980 8/14/1981, 46 FR 41050.

Georgia Power Plant Bowen ....... EPD–AQC–163 ............................................................................... 5/16/1979 1/3/1980, 45 FR 781.

Union Camp ................................ 2631–025–7379–0 .......................................................................... 12/18/1981 4/13/1982, 47 FR 15794.

Blue Bird Body Company ............ 3713–111–8601 .............................................................................. 1/27/1984 1/7/1985, 50 FR 765.

Plant McDonough ........................ 4911–033–5037–0 conditions 10 through 22 ................................. 12/27/1995 3/18/1999, 64 FR 13348.

Plant Yates .................................. 4911–038–4838–0 conditions 19 through 32 ................................. 12/27/1995 3/18/1999, 64 FR 13348.

Plant Yates .................................. 4911–038–4839–0 conditions 16 through 29 ................................. 12/27/1995 3/18/1999, 64 FR 13348.

Plant Yates .................................. 4911–038–4840–0 conditions 16 through 29 ................................. 12/27/1995 3/18/1999, 64 FR 13348.

Plant Yates .................................. 4911–038–4841–0 conditions 16 through 29 ................................. 12/27/1995 3/18/1999, 64 FR 13348.

Plant Atkinson ............................. 4911–033–1319–0 conditions 8 through 13 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

Plant Atkinson ............................. 4911–033–1320–0 conditions 8 through 13 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

Plant Atkinson ............................. 4911–033–1321–0 conditions 8 through 13 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

Plant Atkinson ............................. 4911–033–1322–0 conditions 8 through 13 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

Plant Atkinson ............................. 4911–033–6949 conditions 5 through 10 ....................................... 11/15/1994 3/18/1999, 64 FR 13348.

Plant McDonough ........................ 4911–033–6951 conditions 5 through 10 ....................................... 11/15/1994 3/18/1999, 64 FR 13348.

Atlanta Gas Light Company ........ 4922–028–10902 conditions 20 and 21 ......................................... 11/15/1994 3/18/1999, 64 FR 13348.

Atlanta Gas Light Company ........ 4922–031–10912 conditions 27 and 28 ......................................... 11/15/1994 3/18/1999, 64 FR 13348.

Austell Box Board Corporation ... 2631–033–11436 conditions 1 through 5 ....................................... 11/15/1994 3/18/1999, 64 FR 13348.

Emory University ......................... 8922–044–10094 conditions 19 through 26 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

General Motors Corporation ....... 3711–044–11453 conditions 1 through 6 and Attachment A ......... 11/15/1994 3/18/1999, 64 FR 13348.

Georgia Proteins Company ......... 2077–058–11226 conditions 16 through 23 and Attachment A ..... 11/15/1994 3/18/1999, 64 FR 13348.

Owens-Brockway Glass Container, Inc.3221–060–10576 conditions 26 through 28 and Attachment A ..... 11/15/1994 3/18/1999, 64 FR 13348.

Owens-Corning Fiberglass Corporation.3296–060–10079 conditions 25 through 29 ................................... 11/15/1994 3/18/1999, 64 FR 13348.

* * * * * 

[FR Doc. 2024–30253 Filed 12–19–24; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

42 CFR Parts 424, 483, and 484 

[CMS–1803–CN] 

RIN 0938–AV28 

Medicare Program; Calendar Year (CY) 

2025 Home Health Prospective 

Payment System (HH PPS) Rate 

Update; HH Quality Reporting Program 

Requirements; HH Value-Based 

Purchasing Expanded Model 

Requirements; Home Intravenous 

Immune Globulin (IVIG) Items and 

Services Rate Update; and Other 

Medicare Policies; Correction 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), Department 

of Health and Human Services (HHS). 

ACTION: Final rule; correction. 

SUMMARY: This document corrects 

technical errors in the final rule that 

appeared in the November 7, 2024, 

Federal Register titled ‘‘Medicare 

Program; Calendar Year (CY) 2025 

Home Health Prospective Payment 

System (HH PPS) Rate Update; HH 

Quality Reporting Program 

Requirements; HH Value-Based 

Purchasing Expanded Model 

Requirements; Home Intravenous 

Immune Globulin (IVIG) Items and 

Services Rate Update; and Other 

Medicare Policies’’. 

DATES: This correction is effective 

January 1, 2025. 

FOR FURTHER INFORMATION CONTACT: 

Brian Slater, (410) 786–5229, for home 

health and home IVIG payment 

inquiries. 

For questions about the Home Health 

Quality Reporting Program (HH QRP), 

send your inquiry via email to 

HHQRPquestions@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

In FR Doc. 2024–25441 of November 

7, 2024 (89 FR 88354), there were 

technical and typographical errors that 


ddrumheller on DSK120RN23PROD with RULES1
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Rules and Regulations 104065 

are identified and corrected in the 

Correction of Errors section of this 

correcting document. Accordingly, the 

corrections are effective January 1, 2025. 

II. Summary of Errors 

On page 88375, in the table titled 

‘‘Table 7: Final OASIS Points Table for 

CY 2025’’, we made a typographical 

error in a column heading. 

On page 88376, in the table titled 

‘‘Table 8: Final Thresholds for 

Functional Levels by Clinical Group, 

For CY 2025’’, we made a typographical 

error in a column heading. 

On page 88378, in the table titled 

‘‘Table 9: Low Comorbidity Adjustment 

Subgroups for CY 2025’’, we made 

typographical and technical errors in 

two low comorbidity subgroups/ 

descriptions and the table note. 

On pages 88431 and 88432, in our 

discussion of the Home Health Quality 

Reporting Program (HHQRP) quality 

measures, we made typographical errors 

in calendar year for which the measures 

are adopted. 

III. Waiver of Proposed Rulemaking 

and Delay in Effective Date 

Under 5 U.S.C. 553(b) of the 

Administrative Procedure Act (APA), 

the agency is required to publish a 

notice of the proposed rulemaking in 

the Federal Register before the 

provisions of a rule take effect. 

Similarly, section 1871(b)(1) of the 

Social Security Act (the Act) requires 

the Secretary to provide for notice of the 

proposed rulemaking in the Federal 

Register and provide a period of not less 

than 60 days for public comment. In 

addition, section 553(d) of the APA, and 

section 1871(e)(1)(B)(i) of the Act 

mandate a 30-day delay in effective date 

after issuance or publication of a rule. 

Sections 553(b)(B) and 553(d)(3) of the 

APA provide for exceptions from the 

notice and comment and delay in 

effective date APA requirements; in 

cases in which these exceptions apply, 

sections 1871(b)(2)(C) and 

1871(e)(1)(B)(ii) of the Act provide 

exceptions from the notice and 60-day 

comment period and delay in effective 

date requirements of the Act as well. 

Section 553(b)(B) of the APA and 

section 1871(b)(2)(C) of the Act 

authorize an agency to dispense with 

normal rulemaking requirements for 

good cause if the agency makes a 

finding that the notice and comment 

process are impracticable, unnecessary, 

or contrary to the public interest. In 

addition, both section 553(d)(3) of the 

APA and section 1871(e)(1)(B)(ii) of the 

Act allow the agency to avoid the 30- 

day delay in effective date where such 

delay is contrary to the public interest 

and an agency includes a statement of 

support. 

We believe that this final rule 

correction does not constitute a rule that 

would be subject to the notice and 

comment or delayed effective date 

requirements. This document corrects 

technical errors in the preamble of the 

CY 2025 HH PPS final rule but does not 

make substantive changes to the policies 

or payment methodologies that were 

adopted in the final rule. As a result, 

this final rule correction is intended to 

ensure that the information in the CY 

2025 HH PPS final rule accurately 

reflects the policies adopted in that 

document. 

In addition, even if this were a rule to 

which the notice and comment 

procedures and delayed effective date 

requirements applied, we find that there 

is good cause to waive such 

requirements. Undertaking further 

notice and comment procedures to 

incorporate the corrections in this 

document into the final rule or delaying 

the effective date would be contrary to 

the public interest because it is in the 

public’s interest for providers to receive 

information regarding the relevant 

Medicare payment policy in as timely a 

manner as possible, and to ensure that 

the CY 2025 HH PPS final rule 

accurately reflects our policies. 

Furthermore, such procedures would be 

unnecessary, as we are not altering our 

payment methodologies or policies, but 

rather, we are simply implementing 

correctly the methodologies and policies 

that we previously proposed, requested 

comment on, and subsequently 

finalized. This final rule correction is 

intended solely to ensure that the CY 

2025 HH PPS final rule accurately 

reflects these payment methodologies 

and policies. Therefore, we believe we 

have good cause to waive the notice and 

comment and effective date 

requirements. Moreover, even if these 

corrections were considered to be 

retroactive rulemaking, they would be 

authorized under section 

1871(e)(1)(A)(ii) of the Act, which 

permits the Secretary to issue a rule for 

the Medicare program with retroactive 

effect if the failure to do so would be 

contrary to the public interest. As we 

have explained previously, we believe it 

would be contrary to the public interest 

not to implement the corrections in this 

final rule correction for changes 

effective on November 1, 2024, because 

it is in the public’s interest for providers 

to receive information regarding the 

relevant Medicare payment policy in as 

timely a manner as possible, and to 

ensure that the CY 2025 HH PPS final 

rule accurately reflects our policies. 

Corrections 

In FR Doc. 2024–25441 of November 

7, 2024 (89 FR 88354), we make the 

following corrections: 

1. On page 88375, in the table titled 

‘‘Table 7: Final OASIS Points Table for 

CY 2025’’, header row, third column, 

the column heading ‘‘Points (2023)’’ is 

corrected to read ‘‘Points (2025)’’. 

2. On page 88376, in the table titled 

‘‘Table 8: Final Thresholds for 

Functional Levels by Clinical Group, 

For CY 2025’’, header row, last column, 

the column heading ‘‘Points (2023)’’ is 

corrected to read ‘‘Points (2025)’’. 

3. On page 88378, in the table titled 

‘‘Table 9: Low Comorbidity Adjustment 

Subgroups for CY 2025’’ is corrected as 

follows: 

Table 9: Low Comorbidity Adjustment 

Subgroups for CY 2025 

a. After the third row (entry for 

Circulatory 2) adding the following 

entry: 

b. Removing the 14th row (entry for 

Neoplasms 2). 

c. Following the table, the note 

‘‘Source: CY 2023 Home Health Claims 

Data, Periods that end in CY 2022 

accessed on the CCW July 11, 2024.’’ is 

corrected to read ‘‘Source: CY 2023 

Home Health Claims Data, Periods that 

end in CY 2023 accessed on the CCW 

July 11, 2024.’’. 

4. On page 88431, third column 

a. First full paragraph, lines 6 and 7, 

the phrase ‘‘In 2022, CMS tested’’ is 

corrected to read ‘‘In 2023, CMS tested’’. 

b. Fifth full paragraph, line 2, the 

section heading ‘‘C. Quality Measures 

Currently Adopted for the CY 2024 HH 

QRP’’ is corrected to read ‘‘C. Quality 

Measures Currently Adopted for the CY 

2025 HH QRP’’ 


ddrumheller on DSK120RN23PROD with RULES1ER20DE24.016</GPH>

Atherosclerosis, includes Peri heral Vascular Disease, Aortic Ane 
104066 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Rules and Regulations 

c. Last paragraph, line 2, the year ‘‘CY 

2024’’ is corrected to read ‘‘CY 2025’’. 

5. On page 88432, in the table titled 

‘‘Table 26: Measures Currently Adopted 

for the CY 2024 HH QRP’’ the table 

heading is corrected to read ‘‘Table 26: 

Measures Currently Adopted for the CY 

2025 HH QRP’’. 

Elizabeth J. Gramling, 

Executive Secretary, Department of Health 

and Human Services. 

[FR Doc. 2024–30169 Filed 12–19–24; 8:45 am] 

BILLING CODE 4120–01–P 


ddrumheller on DSK120RN23PROD with RULES1